Curis, Inc. (CRIS)

NASDAQ: CRIS · Delayed Price · USD
3.21
-0.44 (-12.05%)
At close: Jan 18, 2022 4:00 PM
3.25
0.04 (1.25%)
After-hours:Jan 18, 2022 7:36 PM EST
Market Cap294.07M
Revenue (ttm)10.54M
Net Income (ttm)-39.33M
Shares Out91.61M
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,592,252
Open3.69
Previous Close3.65
Day's Range3.20 - 3.69
52-Week Range3.18 - 17.40
Beta2.81
AnalystsBuy
Price Target21.67 (+575.1%)
Earnings DateNov 9, 2021

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid ...

IndustryBiotechnology
IPO DateAug 1, 2000
CEOJames Dentzer
Employees28
Stock ExchangeNASDAQ
Ticker SymbolCRIS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Curis stock is "Buy." The 12-month stock price forecast is 21.67, which is an increase of 575.08% from the latest price.

Price Target
$21.67
(575.08% upside)
Analyst Consensus: Buy

News

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Jan. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

1 week ago - PRNewsWire

Is the Options Market Predicting a Spike in Curis (CRIS) Stock?

Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy ...

LEXINGTON, Mass., Jan. 6, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced posi...

1 week ago - PRNewsWire

Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical O...

LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the ...

2 weeks ago - PRNewsWire

Curis to Present at H.C. Wainwright BioConnect Conference

LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

2 weeks ago - PRNewsWire

Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF

LEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

Other symbols:IBB
1 month ago - PRNewsWire

Curis (CRIS) Moves to Buy: Rationale Behind the Upgrade

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

Curis Appoints John A. Hohneker, M.D.

LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the...

1 month ago - PRNewsWire

Here's Why Curis (CRIS) Could be Great Choice for a Bottom Fisher

Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Stree...

1 month ago - Zacks Investment Research

Down 23.2% in 4 Weeks, Here's Why Curis (CRIS) Looks Ripe for a Turnaround

Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earni...

2 months ago - Zacks Investment Research

Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 7.69% and 14.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Curis Reports Third Quarter 2021 Financial Results and Business Update

LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f...

2 months ago - PRNewsWire

Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced a po...

2 months ago - PRNewsWire

Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Re...

LEXINGTON, Mass., Nov. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

2 months ago - PRNewsWire

Earnings Preview: Curis (CRIS) Q3 Earnings Expected to Decline

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 9, 2021

LEXINGTON, Mass., Nov. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

2 months ago - PRNewsWire

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that...

2 months ago - PRNewsWire

Curis Announces New Preclinical Data Highlighting the Potential of CA-4948 in Multiple Hematologic Malignancies Prese...

LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two ...

3 months ago - PRNewsWire

Why Curis Stock Perked Up in August

The biotech's shares rode the wave of buyout speculation higher last month.

4 months ago - The Motley Fool

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass., Sept. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

4 months ago - PRNewsWire

Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Curis Q2 Earnings

Shares of Curis (NASDAQ:CRIS) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 29.41% year over year to ($0.12), which missed the est...

5 months ago - Benzinga

Curis Reports Second Quarter 2021 Financial Results

LEXINGTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its f...

5 months ago - PRNewsWire

Will Curis (CRIS) Report Negative Q2 Earnings? What You Should Know

Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021

LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

5 months ago - PRNewsWire